Protara Therapeutics, Inc. (TARA)
Nasdaq · Healthcare · Biotechnology
$2.63−2.59%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $155M
- 52-week range
- $2.57 – $7.82
- 52-week change
- −44.56%
- EPS (trailing)
- −$1.36
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Net income
- −$57.4M
- Diluted EPS
- −$1.34
- Free cash flow
- −$56.5M
From the company’s annual report on SEC EDGAR.
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Headquarters: New York, United States · 46 employees · protaratx.com